Eisai Inc.
Global Headquarters:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
Woodcliff Lake
New Jersey
07677
United States
525 articles about Eisai Inc.
-
Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments
5/2/2019
Dr. Harald Hampel hired as Vice President, Global Medical Affairs, Alzheimer's Disease; Dr. Michael Irizarry named Vice President, Clinical Research, Alzheimer's Disease
-
Eisai and Purdue Pharma Announce Buy Out of Purdue's Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
5/1/2019
Eisai Inc. and Purdue Pharma L.P. announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer's Disease.
-
Eisai Selected as Competitive ICT Strategy Company for 2019
4/24/2019
Recognized for Taking on Challenge of Transformation to New Business Models by Integrating Management and Ict Strategies
-
Eisai To Present Research Findings in Epilepsy and Sleep-Wake Disorders at the 2019 American Academy of Neurology Annual Meeting
4/24/2019
Oral presentation highlighting assessment of next-morning residual effects of lemborexant, an investigational agent
-
Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
4/8/2019
Eisai Co., Ltd. has announced that its in-house discovered fibroblast growth factor receptor tyrosine kinase inhibitor E7090 has been granted the SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion.
-
Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
4/5/2019
Motion Sickness Solution Now Available in Convenience Stores
-
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines - April 1, 2019
4/1/2019
Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.
-
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines
4/1/2019
Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.
-
Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
3/29/2019
Eisai Co., Ltd. announced that in the 8th meeting of the Data Safety Monitoring Board for the global Phase III clinical studies on the investigational oral BACE inhibitor elenbecestat in early Alzheimer's disease, the DSMB reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies.
-
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
3/29/2019
Eisai Co., Ltd. announced that in the 8th meeting of the Data Safety Monitoring Board for the global Phase III clinical studies on the investigational oral BACE inhibitor elenbecestat in early Alzheimer's disease, the DSMB reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease
3/22/2019
BioArctic AB announced that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401 in patients with early Alzheimer´s disease.
-
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
-
Eisai to Present Latest Research about Alzheimer's Disease/Dementia Pipeline at The 14th International Conference on Alzheimer's & Parkinson's Diseases
3/22/2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) on March 26-31 in Lisbon, Portugal.
-
Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent
3/22/2019
Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
-
Perhaps the last big hope for a successful Alzheimer’s drug just died. Biogen and its collaboration partner, Eisai, announced they were discontinuing the global Phase III clinical trials of aducanumab in patients with mild cognitive impairment from Alzheimer’s.
-
TRIA to Design New Dementia Discovery Center for Eisai Inc.
3/13/2019
Construction underway on state-of-the-art lab facility in new Alewife Research Center
-
BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease
3/7/2019
BioArctic AB informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
-
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
3/6/2019
The conference will be held from March 7-10 in Miami.
-
FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
2/25/2019
Proposed updated label includes data from CAMELLIA-TIMI 61, the first completed and largest cardiovascular outcomes trial for a weight loss agent